or Try an Advanced Search...

    Technical Analysis for SXTP - 60 Degrees Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.24 1.71% 0.00
    SXTP closed up 1.71 percent on Friday, April 26, 2024, on 52 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical SXTP trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    BB Squeeze Ended Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    MACD Bearish Signal Line Cross Bearish 1.71%
    New 52 Week Closing Low Bearish 1.71%
    Bollinger Band Squeeze Range Contraction 1.71%
    BB Squeeze + Lower Band Touch Range Contraction 1.71%
    Down 3 Days in a Row Weakness 1.71%
    Lower Bollinger Band Touch Weakness 1.71%
    Older End-of-Day Signals for SXTP ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    Lower Bollinger Band Support 2 days ago
    Gap Up Closed 2 days ago
    60 Minute Opening Range Breakdown 2 days ago
    Fell Below Previous Day's Low 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SXTP Chart by TradingView
    Basic chart:

    Profile

    60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Pharmaceutical Infectious Diseases Infection Malaria Covid 19 Dengue Epidemiology Tropical Diseases Vaccine Preventable Diseases Candidiasis Dengue Fever Tick Borne Diseases Treatment Of Infectious Diseases

    Is SXTP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 3 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
    Apr 3 60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
    Mar 14 60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
    Feb 20 60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
    Feb 8 60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
    Jan 31 WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
    Jan 31 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
    Jan 30 WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
    Jan 30 60 Degrees Pharmaceuticals stock sinks on pricing of $2.4M public offering
    Jan 30 60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
    See more SXTP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.65
    52 Week Low 0.222
    Average Volume 181,033
    200-Day Moving Average 0.87
    50-Day Moving Average 0.27
    20-Day Moving Average 0.26
    10-Day Moving Average 0.25
    Average True Range 0.02
    RSI (14) 37.89
    ADX 10.69
    +DI 12.15
    -DI 15.95
    Chandelier Exit (Long, 3 ATRs) 0.23
    Chandelier Exit (Short, 3 ATRs) 0.30
    Upper Bollinger Bands 0.29
    Lower Bollinger Band 0.23
    Percent B (%b) 0.13
    BandWidth 23.15
    MACD Line -0.01
    MACD Signal Line -0.01
    MACD Histogram -0.0001
    Fundamentals Value
    Market Cap 1.38 Million
    Num Shares 5.8 Million
    EPS -0.59
    Price-to-Earnings (P/E) Ratio -0.40
    Price-to-Sales 28.28
    Price-to-Book 0.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.26
    Resistance 3 (R3) 0.26 0.25 0.25
    Resistance 2 (R2) 0.25 0.24 0.25 0.25
    Resistance 1 (R1) 0.24 0.24 0.24 0.24 0.25
    Pivot Point 0.24 0.24 0.23 0.24 0.24
    Support 1 (S1) 0.23 0.23 0.23 0.23 0.22
    Support 2 (S2) 0.22 0.23 0.22 0.22
    Support 3 (S3) 0.22 0.22 0.22
    Support 4 (S4) 0.22